ISDA

Deposition Date 2008-11-11

Release Date 2009-03-31

Last Version Date 2024-04-03

Entry Detail

PDB ID:

3F82

Keywords:

TRANSFERASE

Title:

Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in complex with N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.50 Å

R-Value Free:

0.25

R-Value Work:

0.18

R-Value Observed:

0.18

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:hepatocyte growth factor receptor
Gene (Uniprot):MET
Mutagens:YES
Chain IDs:A
Chain Length:314
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P08581 Pfam ID:PF07714 EC:2.7.10.1

Ligand Molecules

353

Primary Citation

Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily

Schroeder, G.M, An, Y, Cai, Z.W, Chen, X.T, Clark, C, Cornelius, L.A, Dai, J, Gullo-Brown, J, Gupta, A, Henley, B, Hunt, J.T, Jeyaseelan, R, Kamath, A, Kim, K, Lippy, J, Lombardo, L.J, Manne, V, Oppenheimer, S, Sack, J.S, Schmidt, R.J, Shen, G, Stefanski, K, Tokarski, J.S, Trainor, G.L, Wautlet, B.S, Wei, D, Williams, D.K, Zhang, Y, Zhang, Y, Fargnoli, J, Borzilleri, R.M.Show

J.Med.Chem. 52 1251 1254 (2009)

PMID: 19260711 DOI: 10.1021/jm801586s

Abstact

Substituted N-(4-(2-aminopyridin-4-yloxy)-3-fluoro-phenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamides were identified as potent and selective Met kinase inhibitors. Substitution of the pyridine 3-position gave improved enzyme potency, while substitution of the pyridone 4-position led to improved aqueous solubility and kinase selectivity. Analogue 10 demonstrated complete tumor stasis in a Met-dependent GTL-16 human gastric carcinoma xenograft model following oral administration. Because of its excellent in vivo efficacy and favorable pharmacokinetic and preclinical safety profiles, 10 has been advanced into phase I clinical trials.

Legend

Protein

Chemical

Disease

Primary Citation of related structures